Ibalizumab

Drug Profile

Ibalizumab

Alternative Names: 5AB; Hu5A8; Monoclonal antibody 5A8; TMB-355; TNX-355

Latest Information Update: 09 May 2017

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer TaiMed Biologics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors; HIV fusion inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

  • 03 May 2017 Preregistration for HIV-1 infections (Treatment-experienced) in USA (IV)
  • 03 May 2017 TaiMed Biologics requests priority review status for ibalizumab for HIV-1 infections in USA
  • 06 Mar 2017 Theratechnologies acquires commercial rights to ibalizumab from TaiMed Biologics in European Union, Israel, Norway, Russia and Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top